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Abstract
Shiga toxin (Stx) is considered the main virulence factor in Shiga
toxin-producing  (STEC) infections. Previously we reported theEscherichia coli
expression of biologically active Stx by eukaryotic cells and in vitro in vivo
following transfection with plasmids encoding Stx under control of the native
bacterial promoter . Since  genes are present in the genome of lysogenicstx
bacteriophages, here we evaluated the relevance of bacteriophages during
STEC infection. We used the non-pathogenic  C600 strain carrying aE. coli
lysogenic 933W mutant bacteriophage in which the  operon was replaced bystx
a gene encoding the green fluorescent protein (GFP). Tracking GFP expression
using an  Imaging System (IVIS), we detected fluorescence in liver,In Vivo
kidney, and intestine of mice infected with the recombinant  strain afterE. coli
treatment with ciprofloxacin, which induces the lytic replication and release of
bacteriophages. In addition, we showed that chitosan, a linear polysaccharide
composed of d-glucosamine residues and with a number of commercial and
biomedical uses, had strong anti-bacteriophage effects, as demonstrated at in
 and conditions. These findings bring promising perspectives for thevitro in vivo 
prevention and treatment of haemolytic uremic syndrome (HUS) cases.
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Introduction
Infections by Shiga toxin-producing Escherichia coli (STEC) strains 
are a serious public health concern, resulting in diarrhea, hemor-
rhagic colitis, and haemolytic uremic syndrome (HUS).
Stx is the main virulence factor in STEC strains. The stx gene is 
present in the genome of prophages, which are similar to the bac-
teriophage lambda found in the lysogenic form of various E. coli 
strains. Previously we reported that the native promoter of the Stx-
encoding gene can drive expression of the toxin in eukaryotic cells 
in both in vivo and in vitro conditions1,2.
Many questions remain unanswered with regard to the mechanism 
by which STEC infection causes HUS. In particular, we are inter-
ested in understanding how Stx enters the systemic circulation and 
why only very small numbers of bacteria are sufficient to induce 
HUS in humans3.
Based on our previous observations that the native stx gene pro-
moter is active in host cells, we seek to understand the role bac-
teriophages play in the pathogenesis of STEC strains. Recently, it 
was reported that bacteriophages carrying the stx gene are required 
for the development of HUS in the murine model4. Our hypothesis 
is that eukaryotic host cells are transduced with and/or infected by 
Stx-encoding bacteriophages, leading to in vivo dissemination after 
entry in. This would also explain why very small numbers of bacte-
ria are sufficient to cause HUS.
In order to test whether bacteriophages are responsible for the 
induction of HUS, we used an anti-bacteriophage agent to inacti-
vate them. Chitosan, a linear polysaccharide polymer obtained after 
the deacetylation of chitin, the structural element in the exoskeleton 
of crustaceans, possesses strong antimicrobial activity against sev-
eral pathogenic microorganisms5. Its antiviral activity was reported 
on the bacteriophage c2, which infects Lactococcus strains, and on 
bacteriophage MS2, which infects E. coli6, without significantly 
affecting the growth of the bacterial strains7. In order to test our 
hypothesis, which would make Stx-encoding bacteriophages a new 
target for prevention and treatment of STEC infections; we used 
chitosan as an anti-bacteriophage agent both in vitro and in vivo.
For that purpose we employed recombinant phages in which the 
Stx-encoding genes were replaced by the gene encoding the green 
fluorescent protein (GFP). The results demonstrated that STEC 
phages can systemically disseminate in different mouse tissues and 
organs after delivery directly into the stomach of mice. In addition, 
with the present results we demonstrated that chitosan has strong 
inhibitory effects on STEC bacteriophage as demonstrated under 
in vitro and in vivo conditions.
Materials and methods
Strains
The E. coli C600ΔTOX:GFP strain is a lysogenized C600 strain car-
rying the 933W bacteriophage in which the stx gene was replaced 
by the gfp sequence (φΔTOX:GFP)8. The bacterial strain was gen-
erously provided by Dr. Alison Weiss. The enterohemorrhagic 
E. coli (EHEC) EDL933W strain (ATCC 43895) is lysogenic for the 
wild-type bacteriophage from which φΔTOX:GFP was obtained. 
E. coli Y 1090 strain was used in the bacteriophage titration assay 
(ATCC 37197).
Transduction of eukaryotic cells
BHK-21 cells (Syrian hamster kidney fibroblasts from the American 
Type Culture Collection) cells were grown on 12-well plates 
(Nunc) in complete medium (10% fetal bovine serum in DMEM 
medium, Gibco, USA) for use in the transduction assay. Phages 
(φΔTOX:GFP), at a multiplicity of infection (M.O.I) equal to 1, 
were added to BHK-21 cells spread the day before on 12 wells 
plate (Nunc). BHK-21 cells were counted with a Neubauer camera, 
and the bacteriophage titers were measured as described below. 
Transduction of BHK-21 cells was enhanced by centrifugation at 
1,000 × g for 10 min at room temperature as previously reported1. 
After incubation at 37°C for 3 hours, the phage-containing medium 
was removed. Cells were washed twice with phosphate buffered 
saline (PBS) and then incubated in complete medium (DMEM, 
Gibco, USA). Twenty four hours post-transduction, cells were 
washed with PBS, harvested by Trypsin-EDTA incubation and cen-
trifuged at 2,655 × g for 15 minutes. DNA was harvested from pel-
lets after incubation for 5 minutes at 98°C in lysis solution (Tris pH8 
50 mM, SDS 2%, Triton-X100 5%) and the harvested DNA was 
used for PCR. Primers: Up-R 5´CCGCTCGAGACTAGTGCAAAAGC-
GAGCCTGGTAAATAAATATG3´; Up-D 5´GGAATTCCATAT-
GCTCGTTGAGGCATATGAAAATCAGAC3´. The reaction was 
run in a Eppendorf Termocycler at an initial 92°C for 120 seconds 
and then at 92°C for 20 seconds and 60°C for 20 seconds and 72°C 
for 120 seconds for 35 cycles using primers giving a fragment of 
1310 bp on the upstream region of gfp gene into the bacteriophage 
genome.
Bacteriophage induction
The E. coli C600ΔTOX:GFP strain was grown in Luria Broth (LB) 
plus 10 mM CaCl2 and chloroamphenicol (Sigma) (15 μg/ml final 
concentration) overnight (ON) at 37°C under agitation. The ON 
culture was diluted to OD600nm = 0.1 in LB plus 10 mM CaCl2 and 
chloramphenicol (Sigma) (15 μg/ml final concentration). Induction 
was carried out by adding ciprofloxacin to a final concentration of 
40 ng/ml9. Bacteria were incubated for 6 hours at 37°C under agita-
tion. Cultures were then centrifuged at 5000 rpm for 15 minutes. 
The bacteriophage-containing supernatant was filtered with 0.2 μm 
filters and kept at 4°C until the titration assay was performed.
Titration assay
E. coli strain (ATCC 37197) was grown in LB plus ampicillin over-
night at 37°C under agitation. The culture was diluted 1:100 in LB 
plus ampicillin and incubated for 2 additional hours at 37°C under 
agitation. At the end of the incubation, 500 μl samples of the E. coli 
strain were incubated with 5, 50 and 100 μl of a suspension containing 
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bacteriophages for 30 minutes at room temperature. At the end 
of this incubation, 3 ml of Top Agar (Tryptone 1%; NaCl 0.5%; 
Agar 0.7%) plus CaCl2 (10 mM final concentration) was added, and 
plated on LB-Amp agar plates. Plates were incubated at 37°C and 
lysis plaques were visually counted.
Bacteriophage inactivation assay
The φΔTOX:GFP phage was incubated with chitosan (Sigma 
448877) at a final concentration of 5 mg/ml in phosphate buffer 
10 mM, at Ph = 7 for 10 minutes at room temperature, and the bac-
teriophage titers were measured as described in titration assay section. 
Chitosan was also used in the bacteriophage induction assay described 
above. Chitosan was added 2 and 4 hours post-induction and bacte-
riophage titers were analyzed at 6 hours post-induction.
Mice
BALB/c and DBA-2 mice were bred in-house at the animal facility of 
the Microbiology Department of the Sao Paulo University, Brazil. The 
protocol was approved by the Ethics Committee on Animal Experi-
ments of the Institute of Biomedical Sciences (Protocol number 106), 
University of São Paulo. Male mice aged 6 weeks (18 to 20 g) were 
used for the In Vivo Imaging System (IVIS). Immature male and 
female DBA-2 mice (17–21 days of age, approximately 8–11 g 
body weight) were used immediately after weaning for the infec-
tion assays with EDL933W strain (n = 4). Mice were maintained 
under a 12-hour light-dark cycle at 22 ± 2°C and fed a standard diet 
and water ad libitum.
Ethics statement
The experimental protocol of this study followed the ethical princi-
ples for animal experimentation adopted by the Brazilian College of 
Animal Experimentation (COBEA) and was approved by the Ethics 
Committee on Animal Experiments of the Institute of Biomedical 
Sciences (Protocol number 106), University of São Paulo, in accord-
ance with the principles set forth in the Guide for the Care and Use 
of Laboratory Animals (National Institutes of Health, 1985).
EHEC infection
Immature male and female DBA-2 mice (17–21 days of age, approx-
imately 8–11 g body weight) were used immediately after weaning 
for the infection assays (n = 4). E. coli EDL933W strain was used 
for the mouse infection experiments following the protocol previ-
ously reported by Brando and collaborators9. Briefly, the E. coli 
EDL933W strain was grown in Tryptic Soy Broth (TSB, DIFCO, 
BD) overnight at 37°C. The culture was centrifuged at 14,000 rpm 
for 15 minutes and the bacterial pellet washed twice in phosphate 
buffered saline (PBS). Bacterial cells were suspended to a final con-
centration of 3 × 1013 CFU/ml. The bacterial suspension (100 μl) 
was delivered directly into the stomach of mice after 8 hours of 
food starvation, via a gavage needle. After 4 hours of ingesting the 
bacterial suspension, mice were given food and water. Control animals 
received 100 μl of sterile PBS. Survival was observed for one week. 
Both groups were composed by 4 animals.
In vivo chitosan protective effects
Immature male and female DBA-2 were infected with the E. coli 
EDL933W strain, as described above, and treated with 100 μl of a 
chitosan solution at a concentration of 5 mg/ml (500 μg of chitosan 
per mouse) orally administered 2 hours after infection and survival 
was recorded. Chitosan effects were also measured. -month old 
BALB/c mice orally infected with the E. coli C600φΔTOX:GFP 
strain. In vivo bacteriophage induction was carried out with cipro-
floxacin as previously described by Zhang and collaborators9. Two 
2 hours after induction with ciprofloxacin, 100 μl of the chitosan 
solution was administered orally to the mice and GFP dissemina-
tion by IVIS was analyzed.
In Vivo Imaging System (IVIS)
Two-month old BALB/c mice were orally infected with the E. coli 
C600:φΔTOX-GFP strain. Briefly, bacterial cells cultivated overnight 
in LB medium were washed with phosphate buffered saline 
(PBS), centrifuged again and suspended in a 20% sucrose to have 
a concentration of 1 × 1010 CFU. Mice were inoculated orally with 
109 bacterial cells and in vivo bacteriophage excision was carried 
out as described by Zhang and collaborators9. Mice were submitted 
to euthanasia with CO2 inhalation 24 hours later. Blood, spleens, 
kidneys, lungs, brains, intestines, hearts and livers were harvested 
by surgical removal and kept in PBS solution for evaluation of GFP 
expression. GFP was excited at 465nm and detected at 510nm. 
Mice were analysed in a living Imaging 4.3.1 Calipter model (Life 
Sciences).
Statistical analysis
Statistical significance between treatments and controls was ana-
lyzed using the Prism 5.0 software (GraphPad Software), and the 
corresponding P values are indicated in the figures. Data correspond 
to means ± standard errors of the means (SEM) for individual mice. 
Statistical differences were determined using the one-way analysis 
of variance (ANOVA).
Results
Induction of φΔTOX:GFP by ciprofloxacin and chitosan anti-
bacteriophage effects
Lytic induction was triggered in the E. coli C600ΔTOX:GFP strain 
using ciprofloxacin9. We observed a significant decrease in the optical 
density of the bacterial culture after addition of the antibiotic and 
the release of phages into the culture supernatant (Figure 1, panel A 
and B). The bacteriophage titers were determined at different time 
points after lytic induction and a significant increase in the number 
of viable bacteriophages was observed after induction (Figure 1, 
panel B). The effect of chitosan as an anti-bacteriophage agent 
was also examined. To this aim, we added chitosan to the bacterial 
culture 2 or 4 hours post-induction and we observed the complete 
inactivation of the φΔTOX:GFP without measurable toxic effects to 
the bacterial strain (Figure 1, panels A and B).
Transduction of mammalian cells with φΔTOX:GFP
We previously reported the capacity of φΔTOX:GFP to transduce 
macrophages in vitro. To further evaluate the ability of chitosan 
to inhibit bacteriophage transduction, BHK-21 cells were trans-
duced for 3 hours with φΔTOX:GFP, φΔTOX:GFP plus chitosan or 
φΔTOX:GFP previously treated with DNAse. Addition of DNAse 
would eliminate any free bacteriophage DNA in the bacterial lysates. 
As shown in Figure 2, φΔTOX:GFP DNA was detected by PCR in 
exposed mammalian cells, confirming that the virus was proficient 
to transduce this cell line. Similar results were also obtained in 
cells exposed to bacteriophages treated with DNAse (Figure 2). 
However, no phage DNA was detected when BHK-21 cells were 
Page 4 of 19
F1000Research 2014, 3:74 Last updated: 07 JAN 2015
Figure 1. Induction of φΔTOX:GFP by ciprofloxacin and effect of chitosan in vitro. A. Growth curve: the E. coli C600ΔTOX:GFP strain 
was induced with ciprofloxacin and the optical density was measured at 600nm at 0, 2, 4 and 6 hours after induction. Non-induced culture of 
E. coli C600ΔTOX:GFP strain was used as control. Chitosan was added at 2 or 4 hours after induction. B. Bacteriophage φΔTOX:GFP titers: 
bacteriophage titers were determined at 0, 2, 4 and 6 hours post-induction. Chitosan was added at 2 or 4 h post-induction. *p<0.05.
Figure 2. Detection of φΔTOX:GFP DNA in transfected mammalian 
cells. A. PCR on DNA extracted from BHK-21 cells: 24 hours after 
transduction, BHK-21 cells were washed and treated with Trypsin-
EDTA solution. DNA was extracted and PCR was performed. Lane 
1: Cells transfected with φΔTOX:GFP. Lane 2: Cells transfected 
with φΔTOX:GFP previously treated with chitosan. Lane 3: Cells 
transfected with φΔTOX:GFP previously treated with DNAse. Lane 
4. Untreated cells. Lane 5. Positive PCR control (φΔTOX:GFP DNA). 
Lane 6. Negative PCR control. Lane 7. 1 kb ladder (Invitrogen).
infected with φΔTOX:GFP incubated with chitosan, confirming the 
inactivating action of chitosan on φΔTOX:GFP (Figure 2).
GFP detection in mice inoculated with the lysogenic E. coli 
C600ΔTOX:GFP strain 
To demonstrate the in vivo dissemination of φΔTOX:GFP, mice were 
infected with the lysogenic E. coli C600ΔTOX:GFP strain followed by 
gastrointestinal administration of ciprofloxacin. In order to evaluate 
the effect of chitosan in vivo, a group of mice was administered with 
chitosan 2 hours post-induction and a control group of uninfected 
mice was evaluated for auto-fluorescence background control in each 
organ. One day after infection, organs were harvested and examined 
for GFP expression. As shown in Figure 3, GFP was detected in the 
intestine, liver and, to a lesser extent, kidney of mice orally infected 
with the lysogenic E. coli C600ΔTOX:GFP strain and treated with 
ciprofloxacin. Remarkably, administration of chitosan 2 hours after 
infection caused a sharp decrease in GFP detection in organs of 
orally infected mice (Figure 3, panels A and B). Moreover, posi-
tive detection of phages was observed in intestine homogenates and 
blood samples of infected mice after ciprofloxacin induction (data 
not shown). These results indirectly demonstrate that φΔTOX:GFP 
is released by the lysogenic bacterial E. coli strain and systemically 
spread and transduce cells in different mouse organs and tissues 
after oral infection and lytic induction. Another possibility is that, 
the bacteriophage could be taken by pinocytosis by eukaryotic cells, 
and, once inside the cell, GFP or Stx2 are expressed. 
Effect of chitosan on the mortality of mice orally inoculated 
with the EHEC EDL933W strain
In order to evaluate the in vivo effect of chitosan during the infec-
tion process, mice were intragastrically infected with a wild-type 
EHEC EDL933W strain, based on the model described by Brando 
and collaborators10. Another mouse group was also treated with 
chitosan, intragastrically administered 2 hours post-infection, and 
survival was followed for one week. Partial protection was observed 
in mice treated with chitosan as demonstrated by the delay in the 
death time (Figure 4). Mice infected with the EHEC EDL933W 
strain died 72 hours post-infection while mice infected with the 
same strain and subsequently treated with chitosan died 168 hours 
after infection.
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Figure 3. Detection of in vivo GFP expression in mice infected with the lysogenic E. coli C600ΔTOX:GFP strain using In Vivo Imaging 
System (IVIS). A. IVIS Representative image: ciprofloxacin was administered 2 hours post-infection to induce φΔTOX:GFP in vivo. Mice were 
treated with chitosan 2 hours after bacteriophage induction. All mice were sacrificed 24 hours post-infection and brains, hearts, lungs, livers, 
spleens, kidneys and intestines were harvested and analyzed by IVIS. Fluorescence intensity was recorded as photons/sec/cm2, and the 
signal intensity represents the amount of GFP present. B. Graphic of fluorescence intensity on GFP-positive organs. Four animals per group 
were analyzed and the fluorescence intensity was quantified using Living Imaging 4.3.1 in Calipter Life Sciences.
Discussion
Lambda bacteriophages are used as carriers in gene transfer and 
vaccine delivery experiments based on the capacity to in vivo trans-
duce mammalian cells11. Tyler and collaborators recently showed 
that prophage induction is required for renal disease and lethality 
in the EHEC mouse model, suggesting that free bacteriophages 
encoding Stx may play a direct role in the disease4. Our results give 
a further support to that hypothesis and help understand why only 
small numbers of bacteria are usually capable to induce HUS in 
humans3. If bacteriophages are induced in the gastrointestinal tract, 
infect different host cells, and promote Stx expression, a reduced 
number of bacteria would suffice to cause significant damage.
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Dataset 1. Induction of φΔTOX:GFP strain by ciprofloxacin and 
chitosan effect
http://dx.doi.org/10.5256/f1000research.3718.d34269
Induction of φΔTOX:GFP by ciprofloxacin and effect of chitosan 
in vitro. A. Growth curve: the E. coli C600DTOX:GFP strain was 
induced with ciprofloxacin and the optical density was measured at 
600 nm at 0, 2, 4 and 6 hours after induction. Non-induced culture 
of E. coli C600DTOX:GFP strain was used as control. Chitosan was 
added at 2 or 4 hours after induction. B. Bacteriophage φΔTOX:GFP 
titers: bacteriophage titers were determined at 0, 2, 4 and 6 hours 
post-induction. Chitosan was added at 2 or 4 h post-induction. 
*p<0.05
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3. Petruzziello-Pellegrini TN, Marsden PA: Shiga toxin-associated hemolytic uremic 
syndrome: advances in pathogenesis and therapeutics. Curr Opin Nephrol 
Hypertens. 2012; 21(4): 433–40. 
PubMed Abstract | Publisher Full Text 
4. Tyler JS, Beeri K, Reynolds JL, et al.: Prophage induction is enhanced and 
required for renal disease and lethality in an EHEC mouse model. PLoS 
Pathog. 2013; 9(3): e1003236. 
PubMed Abstract | Publisher Full Text | Free Full Text 
The same chitosan protective effects were also observed in vivo 
based on mice infected with the wild-type EHEC EDL933W strain 
which is lysogenic for the same bacteriophage used to generate the 
E. coli C600ΔTOX:GFP strain. The fact that only partial protection 
was observed in mice infected with the E. coli C600ΔTOX:GFP 
strain and subsequently treated with chitosan may be due to the 
short half-life of the compound12.
Altogether, these findings suggest a paradigm change on the role 
of bacteriophages in STEC infections, indicating that these bacte-
riophages have a pivotal role on the development of HUS. The pre-
sent observations further suggest that prophylaxis and treatment of 
human bacterial infections carrying virulence factors on lysogenic 
bacteriophages could require targeting of the bacteriophages instead 
of, or as well as, the bacteria and toxins involved.
Data availability
F1000Research: Dataset 1. Induction of φΔTOX:GFP strain by 
ciprofloxacin and chitosan effect, 10.5256/f1000research.3718.
d3426913 
Author contributions
LVB designed, performed experiments, analyzed data and wrote the 
manuscript; LCSF provided advice on experimental design, data 
interpretation, obtained funding and critical reading of the manu-
script; JHA, RJFB, MDC and MFB performed experiments and pro-
vided advice on experimental design, MJRR-WBL, MSP, PDG and 
RCCF provided advice on experimental design. EGS provided criti-
cal feed-back and editing on the manuscript. All authors contributed 
to the writing and approved the final content of the manuscript.
Competing interests
No competing interests were disclosed.
Grant information
This work was supported by PICT 2411 from the Agencia Nacional 
de Promoción Científica y Tecnológica, Argentina (to L.V.B) and 
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), 
Brazil (to L.C.S.F). LVB and PDG are members of the Research 
Career of CONICET (Consejo Nacional de Ciencia y Tecnología).
The funders had no role in study design, data collection and analysis, 
decision to publish, or preparation of the manuscript.
Acknowledgments
We would like to acknowledge Dr. Alison A. Weiss for providing 
strain E. coli C600: ΔTOX-GFP.
Figure 4. Treatment with chitosan delays death of mice infected 
with the EHEC EDL933W strain. Mice were infected orally with the 
EHEC EDL933W strain. Controls did not receive chitosan (dots and 
broken line) and the experimental group received chitosan 2 hours 
post-infection (square and fill line). Survival rates were followed for 
one week.
In previous reports, we showed that the native phage promoter con-
trolling Stx expression is active in eukaryotic cells both in vitro1 
and in vivo2 conditions. Based on these results, we sought to evalu-
ate whether bacteriophages could be considered a target for treating 
STEC infections. To this aim, we used GFP as an in vitro and in 
vivo reporter of phage dissemination based on a lysogenic E. coli 
C600ΔTOX:GFP strain and following bacteriophage induction. 
GFP expression was observed in liver, intestine and kidney of mice 
orally infected with the lysogenic strain and subsequently exposed 
to phage inducing conditions by oral administration with cipro-
floxacin. Of particular relevance was the observation that chitosan, 
a natural polysaccharide polycationic polymer, exerted a direct 
inactivation effect on φΔTOX:GFP in vitro and drastically reduced 
the detection of fluorescence in mice orally infected with the lyso-
genic E. coli C600ΔTOX:GFP strain. Our findings indicate that 
chitosan possesses strong anti-bacteriophage effects in vitro and 
probably also in vivo, as demonstrated with the lysogenic E. coli 
C600ΔTOX:GFP strain. This positively charged polymeric polysac-
charide has been reported to inhibit other bacteriophages and prob-
ably acts through electrostatic interactions with negatively charged 
capsid proteins6. Based on these effects we propose that chitosan 
could be a viable alternative for the treatment of STEC infections. 
Chitosan is already used in food and medicine, and it is harmless 
to humans, making it a cheap and safe option for this application.
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   Current Referee Status:
Version 2
 05 January 2015Referee Report
doi:10.5256/f1000research.5299.r5927
 Mikael Skurnik
Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland
First of all I am sorry for the long delay in my getting back to this evaluation. While the authors have
replied adequately to some of my comments there are some that are not. I will deal them below.
Major points:
 It is not enough to write the data of the dose response experiments in the reply. The results of thePoint 1.
dose response experiments should be integrated into the main article.
Inclusion of the mouse experiment (Fig. 4) in the article is not acceptable and should be deletedPoint 2. 
completely. In addition to having relatively small number of mice per group, the use of both male and
female mice in the experiments is not appropriate as the responses can vary between the sexes. This and
the small numbers of mice could be the reason for non-consistent killing results. In addition, it is not clear
either from the authors' reply of from the text and the figure, how many mice were actually in the
experiment. The figure 4 indicates that 50 % of both mouse groups died. How many mice was 50%, one
or two? I have hard time to believe that two non-treated mice both died after 72 hr and two
chitosan-treated both after 168 hr after infection and at the same time two mice in both groups survived.
Therefore the mouse experiments in my opinion do not have any significance to one or other direction and
should not be included in the present article.
 While the both controls the authors used are OK, they don't control the effect of ciprofloxacin inPoint 3.
the experiment. Chitosan could also neutralize ciprofloxacin and thereby rescue the bacterial growth. The
E. coli C600 strain is very widely used strain and should be easy to get. Preferentially it should be from the
same source from where the lysogenic strains were obtained. I have the strain also in my strain collection
and I can send it to the authors if they don't find it elsewhere.
OKPoint 4. 
While the response seems OK, I don't find anywhere in the article the results and the additionalPoint 5. 
figure. These should be integrated to the article.
Even though the C600 strain is not invasive, bacteria may be taken up by endocytosis andPoint 6.  
thereby enter the organs. The authors should exclude this possibility. While it would be difficult to detect
the bacteria from intestinal tissue, other organs should be sterile.If the authors cannot see any bacterial
growth from the sterile organs, that would be a sufficient control.
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growth from the sterile organs, that would be a sufficient control.
See point 2 above.Point 7. 
All previous were all addressed adequately.Minor points 
Please check carefully the text on page 4 right column top paragraph.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
 29 December 2014Referee Report
doi:10.5256/f1000research.5299.r6885
 Cristina Ibarra
Laboratory of Physiopathology, University of Buenos Aires, Buenos Aires, Argentina
This is an interesting paper where the authors have examined the hypothesis that  the stx-carrying
prophage upon induction  are required for the development of HUS in the murine model. Eukaryotic in vivo
host cells would transduce these phages, leading to increase of Stx production in the target organs. This
would explain why very small numbers of bacteria are sufficient to cause HUS. The authors have also
examined the anti-bacteriophage effects of chitosan  and  and demonstrated that chitosan in vivo in vitro
has strong inhibitory effects on STEC bacteriophage and suggest that it could be a prophylactic for the
prevention and treatment of HUS patients.
In general, the presented study is conducted straight forward, is written concisely and the applied
methodology is adequate.
I recommend indexation of this article without changes.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
 09 September 2014Referee Report
doi:10.5256/f1000research.5299.r6090
 Raúl Raya
Genetics and Molecular Biology, Centro de Referencia Para Lactobacilos (CERELA), San Miguel de
Tucumán, Argentina
I consider the authors have satisfactorily answered all my comments and that the manuscript is
acceptable.
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Should the phrase:  “The fact that only partial protection was observed in mice infected with the E.
coli C600ΔTOX:GFP strain and subsequently treated with chitosan may be due to the short half-life of the
.” instead be: “compound The fact that only partial protection was observed in mice infected with
the wild-type EHEC EDL933W strain and subsequently treated with chitosan may be due to the short
”?half-life of the compound
 
The authors should indicate the concentration of DNAase used.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Version 1
 17 April 2014Referee Report
doi:10.5256/f1000research.3984.r4510
 Raúl Raya
Genetics and Molecular Biology, Centro de Referencia Para Lactobacilos (CERELA), San Miguel de
Tucumán, Argentina
The article written by Amorim  describes the anti-phage activity of chitosan on two variants (wild typeet al.
and a derivative where the  gene was replaced by the  gene) of the temperate Shiga-toxinstx gfp
producing phage EDL933W. The anti-phage activity was evaluated both  and . The authorsin vivo in vitro
suggest that chitosan could be a viable alternative for the treatment of STEC infections.
 
Major:
Phage Induction/anti-phage effects of chitosan/Figure 1:
It seems that chitosan not only sequesters free-phage particles, but also stimulates the growth of
uninduced cells (see induced cells treated with chitosan 2 hours post-induction reached higher final OD
values). So, does chitosan inhibit the induction process of the temperate phage? Or, does chitosan also
adsorb/inactivate ciprofloxacin? Even though in the Materials and Methods a “Bacteriophage inactivation
assay” is described, no data is presented. A dose-response curve should be presented, to determine the
phage binding (inactivation) capacity of chitosan.
 
In vivo experiments:
If the authors suggest that Stx phages, rather than bacterial cells, may be responsible for the development
of the STEC infections, why they did not use purified phage in  experiments? Does chitosanthe vivo
adsorb/inactivate the Shiga-toxins? If so, may it explain the delayed response observed in Figure 4
(“EDL933W plus chitosan”)?
 
Minors:
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Minors:
 
Abstract:
Provide a reference after “… plasmids encoding Stx under control of the native bacterial promoter.”
 
Change “  K12 strain” to “  C600 strain”.E. coli E. coli
 
Materials and Methods:
Delete “… was generously provided by Dr. Luis Carlos de Souza Ferreira, LDV-USP, Brazil.”, since
Dr. Ferreira is one of the authors of the manuscript.
 
Check the sentence “…was generously provided by Dr. Alison Weiss”; it is repeated twice in the
Materials and Methods, and also in the Acknowledgments.
 
Change “This is a non-pathogenic phage…” to “This is a non-pathogenic cell…”
 
Change “…complete DMEM medium” to “DMEM medium”. Or, if the “complete DMEM medium”
contains 10% fetal bovine serum, change “…complete DMEM medium” for “…complete medium”.
 
Please, indicate how DNA was harvested.
 
Change “Tris pH8 50mM” to “Tris pH8 50 mM”.
 
Change “BALB/c mice were bred…” to ““BALB/c and DBA-2 mice were bred…”
 
Change “…under a 12-h light-dark…” to “…under a 12-hour light-dark…”.
 
Delete the sentence “Two-month old BALB/c mice … and GFP dissemination by IVIS was
analyzed”. It is redundant.
 
Results:
Figure 1B: Should “Bacteriophage/ml” be “PFU/ml”? Why phage titers are so low?
 
Figure 1A: Change “hs” for “hours” or “h”.
 
Figure 2: Lanes 5 and 6 should read: “positive PCR control” and “negative PCR control”,
respectively. In lane 78, indicate in the figure the kb values of the ladder.
 
Delete “viable” in “viable phages”. Were phages transduced or adsorbed to mammalian cells?
 
The sentence “Mice were orally challenged with a wild-type EDL933W” is not correct, since there
was a direct delivery of bacterial cells into the stomach of mice.
 
Discussion:
 
Check “deliv-ery”
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
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 No competing interests were disclosed.Competing Interests:
Author Response 01 Aug 2014
, UNQ, ArgentinaLeticia Bentancor
Phage Induction/anti-phage effects of chitosan/Figure 1:
The higher final OD values determined on the cells treated with chitosan 2 hours post-induction,
versus the OD value determined on un-induced cells, is not statistically significant. However, we
tested if chitosan is capable of inactivating ciprofloxacin. Ciprofloxacin and chitosan were
incubated for 10 minutes at room temperature with chitosan at 5mg/ml. After pre-incubation, the
mix was used to induce bacteriophage excision. To see a more significant effect on bacteriophage
excision, the induction was incubated overnight. The OD value measured showed a non-significant
difference between non-induced culture and induced culture with the antibiotic pre-incubated with
chitosan (the experiment was performed in triplicate).
On the other hand, purified bacteriophages were incubated with chitosan, and bacteriophage
inactivation was observed with a lysis plaques assay. Bacteriophages were incubated for 10
minutes at room temperature with chitosan at 5mg/ml. After incubation, bacteriophage inactivation
was evaluated. The bacteriophage solution containing a titer of 4x10 pfu/ml was 100% inactivated
after chitosan incubation. The assay was performed in triplicate. This result showed the capacity of
chitosan to inactivate bacteriophage .in vitro
Also, we did a dose-response curve of chitosan. We used 5mg/ml, 2.5mg/ml, and 1mg/ml of
chitosan on purified bacteriophage solution. To evaluate it, the bacteriophage solution was
incubated for 10 minutes at room temperature with the different doses of Chitosan and the
bacteriophage inactivation was evaluated with a lysis plaques assay. Chitosan at 1mg/ml lost the
inactivation activity on the bacteriophages. Chitosan at 5mg/ml and 2.5 mg/ml showed a 100%
efficiency on bacteriophage inactivation, however, 1mg/ml of chitosan showed a loss of
inactivation, showing between 5-10% of bacteriophage inactivation. This experiment was
performed in triplicate.
 In vivo experiments:
Chitosan was analyzed  and  on fDTOX:GFP. Inactivation of fDTOX:GFP wasin vitro in vivo
observed  with a lysis plaques assay. On the other hand, a decrease of GFP was observed in vitro
 by IVIS. These results shown that chitosan has the capacity to inactive bacteriophages inin vivo
absence of Shiga-toxins. A direct action of chitosan on Shiga toxin was not evaluated in this work
since we do not have purified Stx2 for such experiments. The authors are working on murine
infection with fStx2, but the results obtained will be part of a new publication.
 
Abstract:
Provide a reference after “… plasmids encoding Stx under control of the native bacterial
promoter.”
The reference was provided. 
 
Change “  K12 strain” to “  C600 strain”.E. coli E. coli
3
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Change “  K12 strain” to “  C600 strain”.E. coli E. coli
The change was made.
Materials and Methods:
Delete “… was generously provided by Dr. Luis Carlos de Souza Ferreira, LDV-USP,
Brazil.”, since Dr. Ferreira is one of the authors of the manuscript.
Answer:  We deleted “… was generously provided by Dr. Luis Carlos de Souza Ferreira,
LDV-USP, Brazil.”
 
Check the sentence “…was generously provided by Dr. Alison Weiss”; it is repeated twice in
the Materials and Methods, and also in the Acknowledgments.
 We deleted the sentence in the sub-section “ ” of materialTransduction of eukaryotic cells
and methods section. 
 
Change “This is a non-pathogenic phage…” to “This is a non-pathogenic cell…”
We changed “This is a non-pathogenic phage…” to “This is a non-pathogenic cell…”.
However, this non-pathogenic cell produces the excision of a non-pathogenic phage.
 
Change “…complete DMEM medium” to “DMEM medium”. Or, if the “complete DMEM
medium” contains 10% fetal bovine serum, change “…complete DMEM medium” for
“…complete medium”.
Complete DMEM medium contains 10% fetal bovine serum, so, we changed for the second
option “…complete medium”.
 
Please, indicate how DNA was harvested.
Cells were harvested using Trypsin-EDTA solution. After that, DNA was harvested from
pellets by incubation with lysis solution described in material and methods. We included “by
Trypsin-EDTA incubation” to clarify the procedure.
 
Change “Tris pH8 50mM” to “Tris pH8 50 mM”.
The change was made.
 
Change “BALB/c mice were bred…” to ““BALB/c and DBA-2 mice were bred…”
 We changed “BALB/c mice were bred…”  for ““BALB/c and DBA-2 mice were bred…”
 
Change “…under a 12-h light-dark…” to “…under a 12-hour light-dark…”.
The change was made.
 
Delete the sentence “Two-month old BALB/c mice … and GFP dissemination by IVIS was
analyzed”. It is redundant.
We have two different mouse models. First, we have the model used to analyze GFP
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We have two different mouse models. First, we have the model used to analyze GFP
dissemination in which we used two months old mice. Second, we have the model used to
analyze protection effect in which we used immature mice. For this reason we clarify the
model every time. Let me know if you consider that we need to delete the sentence  
“Two-month old BALB/c mice … and GFP dissemination by IVIS was analyzed”.
Results:
Figure 1B: Should “Bacteriophage/ml” be “PFU/ml”? Why phage titers are so low?
Bacteriophage/ml was changed to PFU/ml as reviewer suggested. See below. It is true that
bacteriophage titers are low. An optimization for bacteriophage purification was done to
obtain a higher titer of bacteriophage. The antibiotics used to induce C600DTOX:GFP was
selected as an alternative for mitomycin C. The efficiency of bacteriophage induction is
strain dependent.  Zhang and collaborators reported a titer equal to 1,3x10  pfu/ml using
ciprofloxacin but they used pathogenic strain  O157:H7.  We also observed a higherE. coli
titer inducing the EDL933W strain, for this reason we suppose that the low titer observed is
dependent on the strain used.
 
Figure 1A: Change “hs” for “hours” or “h”.
 The change was made.
 
Figure 2: Lanes 5 and 6 should read: “positive PCR control” and “negative PCR control”,
respectively. In lane 78, indicate in the figure the kb values of the ladder.
The changes were made.
 
Delete “viable” in “viable phages”. Were phages transduced or adsorbed to mammalian
cells?
We deleted “viable” in “viable phages”. In this context, phages purified from tissue were
detected by lysis plaque assay.
 
The sentence “Mice were orally challenged with a wild-type EDL933W” is not correct, since
there was a direct delivery of bacterial cells into the stomach of mice.
 The sentence “Mice were orally challenged with a wild-type EDL933W” was change by
“Mice were intragastrically infected with a wild-type EDL933W”.
Discussion:
Check “deliv-ery”
We did not find deliv-ery in the Discussion section.
 No competing interests were disclosed.Competing Interests:
 31 March 2014Referee Report
doi:10.5256/f1000research.3984.r4170
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 Mikael Skurnik
Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland
The paper by Amorim deals with the role of bacteriophages in STEC-infections. The authors haveet al. 
earlier demonstrated that the genes can be expressed within eukaryotic cells, provided thestx 
prophage-carried DNA is introduced there in naked form, i.e., in transfected plasmids. In the presentstx-
work, the authors wanted to test/prove the hypothesis that the carrying prophage upon induction stx- in
could contribute to the toxin production. They also tested whether the polysaccharide chitosan hasvivo 
anti-  phage effect. I have some major and minor points:stx
Major
Bacteriophage inactivation assay: The experimental design of the bacteriophage inactivation
assay uses only one concentration of chitosan. To demonstrate specificity, dose dependence
should be demonstrated. In addition, the  dose of chitosan was not indicated in the methods in vivo
section (100 µl/mouse of 5 ml/ml chitosan was given orally to mice as indicated in the Effect of
 section.chitosan in vivo
 
The mouse experiments were performed with too small a number of mice.
 
Figure 1A of growth curves is missing a crucial control. What happens to E. coli C600 under the
ciprofloxacin treatment?
 
Figure 1B: The lack of the 4 hr column in chitosan 4h post-induction does not seem logical to me.
There should be a ca 6000 PFU/ml column similar to that one in the induced 4hr sample. This
discrepancy should be explained.
 
Figure 2: the PCR experiment does not provide evidence of transduction. The definition of
transduction is that DNA moves from one cell to another. PCR detects the phage DNA either free in
the cell cytoplasm or packed in endocytosed phage particles. Therefore, the authors need to
demonstrate that infective phage particles disappear from infected cells. The experiment also does
not exclude the possibility that phage particles are just adsorbed on the cell surface.
 
The experiment reported in figure 3 should also include bacterial counts from the organs as it is
very likely that live E. coli bacteria, after a massive dose of 10  bacteria per mouse, end up in the
organs. Therefore the authors should demonstrate that the GFP response is not from bacteria
infected by the GFP-phages.
 
The Figure 4 experiment was performed with only 4 mice. Such an experiment should not be
shown in a publication. In addition, different chitosan doses should be tested here also.
Minor
Introduction, paragraph 3: This statement on the low number of bacteria during infection should
be backed up with a reference.
 
Materials and Methods: Dr Alison Weiss is thanked twice for same strain. One time should be
enough. In addition, in the acknowledgements she is thanked a third time. The bacterial strain
designation in the latter is given differently than elsewhere in the text.
 
Transduction of Eukaryotic Cells: C600ΔTOX:GFP is a bacterial strain, not a non-pathogenic
13
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Transduction of Eukaryotic Cells: C600ΔTOX:GFP is a bacterial strain, not a non-pathogenic
phage.
 
EHEC infection: The final concentration of CFU/100µl/mouse needs revision.
 
Figure 2 legend: The path the sample takes in the gel is called the lane, not line.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
Author Response 01 Aug 2014
, UNQ, ArgentinaLeticia Bentancor
Major:
A dose-response curve of chitosan was done. We used 5mg/ml, 2.5mg/ml and 1mg/ml of
chitosan on purified bacteriophage. To evaluate it, the bacteriophage solution was
incubated for 10 minutes at room temperature with the different doses of chitosan and the
bacteriophage inactivation was evaluated with a lysis plaques assay. Chitosan at 1mg/ml
lost the inactivation activity on the bacteriophages. Chitosan at 5mg/ml and 2.5 mg/ml
showed a 100% efficiency on bacteriophage inactivation, however, 1mg/ml of chitosan
showed a loss of inactivation, showing between 5-10% bacteriophage inactivation. This
experiment was performed in triplicate.
The effect of chitosan  was evaluated using a final concentration of 5mg/ml ofin vivo
chitosan solution. Each mouse received 100ml, so, the dose used was 500mg/mouse.
The Material and Methods section was changed as follows:
“Immature male and female DBA-2 infected, as described previously, were treated with
100ml of a chitosan solution at a concentration of 5 mg/ml (500 mg of chitosan per mouse)
was orally administrated 2 hours after infection and survival was observed.”
 
The experiment was shown as a preliminary result and this work it is a short communication.
The model used has some experimental problems for the ages of mice used. The
experiment was started using 6 mice per group, but some mice died after inoculation and
not for the infection. For this reason, we had shown only 4 mice per group. We repeat the
experiment, and again we have the same problem, however, we can see the same partial
effect of chitosan . To further analyze the effect observed, we will report the results onin vivo
a new publication with more details. 
 
The controls we used were:
Non-induced  C600DTOX:GFP (as a negative control) in which we canE. coli
observe the normal growth of bacteria without bacteriophage induction
Induced  C600DTOX:GFP (as a positive control) in which we can observe howE. coli
bacteriophage induction affect the growth of bacteria.
 
If you are thinking about  C600 in absence of lisogenic fDTOX:GFP, we do not have accessE. coli
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If you are thinking about  C600 in absence of lisogenic fDTOX:GFP, we do not have accessE. coli
to this strain. But, we think that the controls used are well done. As an observation, we can said
that no significant change in the growth was observed on  Y1090 used for bacteriophageE. coli
titration assay.
The observation is right; we made an error in the graph. The values were checked and the
correct value was added to the new graph.
 
We agree with the definition of transduction, it is the process by which DNA is transferred
from one cell to another by a virus. In our previous paper, we used the same definition to
evaluate the capacity of fDTOX:GFP to transduce macrophages. In this case, we observed
GFP expression and we concluded that macrophages were transduced by fDTOX:GFP. In
this report, we did a different approach and we use PCR to detect bacteriophage DNA
inside the cell.
After your opinion, we did two assays. First, bacteriophages inside the cell were analyzed
for titration assay. Second, as a preliminary data, fStx2 was used to transduce Vero cells, as
a representative Stx2-susceptible cell line. 
Infective bacteriophage particles were not detected on transduced cells. The assay was
made using lysis plaque assay of cellular extracts.
Results:
In order to analyze the transduction by an additional method, Vero cells were transduced
with fStx2 and cytotoxicity induced by Stx2 was evaluated by microscopy. Vero cells
transduced with fStx2 (  showed a similar cytotoxicity to that of cells incubated with 1panel A)
CD50 of purified Stx2 ( ). No cytotoxic effects were observed in non-treated Veropanel B
cells ( ). Vero cells transduced with a M.O.I. = 0,0625 did not shown cytotoxic effect,panel D
demonstrating the specificity of the effect observed by fStx2 ( ).panel D
 
Materials and Methods:
 
 .In vitro evaluation of the capacity of Bacteriophage 933W to transduce Vero cells
 EDL933W (ATCC 43895) was used to purify fStx2.  EDL933W strain wasE. coli E. coli
grown in Luria Broth (LB) overnight (ON) at 37°C under agitation. The ON culture was
diluted to OD600nm = 0.1 in LB. Induction was carried out by adding ciprofloxacin to a final
concentration of 40 ng/ml . Bacteria were incubated for 6 hours at 37°C under
agitation. Cultures were then centrifuged at 5000 rpm for 15 minutes. The
bacteriophage-containing supernatant was filtered with 0.2 mm filters, precipitated and
purified. Briefly, supernatant was incubated on ice with a PEG-8000/NaCl solution for 30
minutes. After that, the solution containing bacteriophages was centrifugated and washed.
The pellet was resuspended in STE buffer (1ml of Tris pH8, 0,2ml of 0,5M EDTA, 2ml of 5M
NaCl, water up to 100ml). Phages at a multiplicity of infection (M.O.I) equal to 1 were added
to Vero cells. Transduction of Vero cells was enhanced by centrifugation at 1000 x g for 10
min at room temperature. After 24 hours post transduction, cells were examined by
microscopy using Nikon Eclipse TE2000 (NIS-Elements imaging software) equipped with a
CCD camera. Dilutions of fStx2 were made to demonstrate specificity. Vero cells were
incubated with purified Stx2 as positive control.
 
. Additional figure  evaluation of the capacity of Bacteriophage 933W to transduceIn vitro
8 in main text
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. Additional figure  evaluation of the capacity of Bacteriophage 933W to transduceIn vitro
 . Vero cells transduced with fStx2 (M.O.I. = 1). . Vero cells incubated withVero cells. A B
purified Stx2. . Vero cells transduced with a M.O.I. = 0,0625. . Vero cells with notC D
treatment.
 
E. coli C600DTOX:GFP is not an invasive bacteria. Also,  O157:H7 is a non invasiveE. coli
strain; for this reason we do not check for bacteria in organs. Bacteria were checked only on
lungs samples, just to see if the inoculation was right. Bacteria were not detected in lungs.
The dose used was selected after a previous experiment in which we evaluated the
sensibility of IVIS in our system. GFP is not the best fluorescent protein for IVIS system; so,
we needed to use a high dose of bacteria.  As we described in this work, bacteriophages
were detected by lysis plaques assay in intestine homogenates and blood samples of
infected mice. It is important to do a highlight in the case of intestine sample, as it is very
difficult to find  C600DTOX:GFP. First, because the huge amount of bacteria presentE. coli
in the sample, and also, because the bacteria lysis induced by bacteriophage excision.
 
The experiment was shown as a preliminary result and this work it is a short communication.
The model used has some experimental problems for the ages of mice used. The
experiment was started using 6 mice per group, but some mice died after inoculation and
not for the infection. For this reason, we had shown only 4 mice per group. We repeat the
experiment, and again we have the same problem, however, we can see the same partial
effect of chitosan . To further analyze the effect observed, we will report the results onin vivo
a new publication with more details. 
 
Minor:
The statement “…very small numbers of bacteria are sufficient to induce HUS in humans…”
is taking the data published recently, in which the authors demonstrated that a
concentration of Stx2 as low as 10 fM is able to induce ribosome damage and to modulate
selected cell signaling pathways that change cellular functions. If 10 fM of Stx2 is enough,
very small numbers of bacteria should be sufficient to induce HUS (Petruzziello-Pellegrini &
Marsden, 2012).
 
We deleted the sentence “…was generously provided by Dr. Alison Weiss” in the
sub-section “Transduction of eukaryotic cells” of material and methods section.
 
We changed “This is a non-pathogenic phage…” to “This is a non-pathogenic cell…”.
However, this non-pathogenic cell produces the excision of a non-pathogenic phage.
The dose is correct. We used a dose of 3 × 10  CFU/mice in a volume of 100 ml.
 
Line was changed for Lane.
 No competing interests were disclosed.Competing Interests:
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